Previous 10 | Next 10 |
Ionis Pharmaceuticals ([[IONS]] -22.5%) has lost almost a fifth after announcing that the partner Roche Holding ([[RHHBY]] -3.3%) has discontinued the dosing in the Phase III GENERATION HD1 study for Tominersen in manifest Huntington's disease (“HD”).An investigational...
Gainers: Dolphin Entertainment (DLPN) +163%.Benitec Biopharma (BNTC) +88%.Liquid Media (YVR) +51%.Takung Art (TKAT) +35%.Evolve Transition Infrastructure (SNMP) +27%.Genius Brands International (GNUS) +17%.The ONE Group Hospitality (STKS) +17%.Glory Star New Media (GSMG) +16%.Funko ...
Gainers: Benitec Biopharma (BNTC) +71%, Hoth Therapeutics (HOTH) +26%, Aerpio Pharmaceuticals (ARPO) +12%, Soliton (SOLY) +11%, China Jo-Jo Drugstores (CJJD) +9%.Losers: Frequency Therapeutics (FREQ) -75%, Windtree Therapeutics (WINT) ...
Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...
Gainers: [[CHMA]] +13.7%. [[RAIL]] +8.3%. [[AMTX]] +7.7%. [[BBGI]] +6.6%. [[NEWT]] +4.9%.Losers: [[WVE]] -15.4%. [[RAVN]] -8.6%. [[DSP]] -7.9%. [[CLSD]] -7.7%. [[PYPL]] -5.7%. For further details see: CHMA, RAIL, WVE and RAVN among after-hours movers
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exe...
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2020 Q4 earnings call. For further details see: Wave Life Sciences Ltd. 2020 Q4 - Results - Earnings Call Presentation
Wave Life Sciences Ltd. (WVE) Q4 2020 Results Earnings Conference Call March 4, 2021, 08:00 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Michael Panzara - Chief Medical Officer, Head of Therapeutics Discovery and Develo...
Wave Life Sciences (WVE): Q4 GAAP EPS of -$0.59 beats by $0.03.Revenue of $9.44M (+293.3% Y/Y) misses by $0.31M.Press Release For further details see: Wave Life Sciences EPS beats by $0.03, misses on revenue
Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021 Moving towards first patient dosing in thre...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...